Tenaya Q2 Loss Widens on $21.8M Impairment, Cash Runway Extended to Q3 2027
TNYA sits 41% above its 52-week low of $0.532.
Summary
Tenaya's Q2 net loss swelled to $43.4M, largely from a $21.8M non-cash impairment tied to the early termination of its manufacturing facility lease. The charge overshadows a $10M upfront payment from the Alnylam collaboration, which pushed the cash runway out to Q3 2027. Operating expenses did decline year-over-year, partly due to the lease exit and ongoing cost cuts. The company also laid out a clear clinical roadmap: additional interim data for TN-201 and TN-401 in Q4 2026, pivotal trial discussions for both programs in the same quarter, and at least one Phase 2 start for TN-301 in the second half of 2027. With shares trading near $0.75 and a market cap around $170M, the extended runway and upcoming catalysts are critical for a company that faces delisting risk and high dilution potential.
At the time of this announcement, TNYA was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $170.3M. The 52-week trading range was $0.53 to $2.35. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.